Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 701–800 of 2,053
Bera, M., Gupta, A. K., Ahmed, R., Baidya, A., & Guha, M. K. (2023) · Clinical Diabetology · doi:10.5603/cd.95828 · Cited by 6
Diabetes and osteoporosis: a two-sample mendelian randomization study
Qu, Y., Zhu, Z., Li, J.-X., Zhang, W., Chen, Q., Xia, C.-L., Ma, J.-N., Ou, S., Yang, Y., Qi, Y., et al. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07430-0 · Cited by 6
“Compared to T2D, T1D typically presents at a younger age at diagnosis ( 35 years) with a lower body mass index (BMI, 25 kg/m 2 ) and is characterized by positivity for insulin-related antibodies [25].”
BackgroundNovodvorský, P., Thieme, L., Laňková, I., Mráz, M., Taybani, Z. J., Bótyik, B., Stella, P., Vytasil, M., Lauand, F., Bonnemaire, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01582-x · Cited by 7
“Correspondingly, MDI regimen has been the last intensification step in the therapeutic guidelines for management of hyperglycaemia in T2D after non-pharmacological interventions, use of oral antidiabetic medication(s) and basal or premixed insulins [1–5].”
BackgroundBouchi, R., Izumi, K., Ishizuka, N., Uemura, Y., Ohtsu, H., Miyo, K., Tanaka, S., Satoh‐Asahara, N., Hara, K., Odawara, M., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14227 · Cited by 10
Incident Cancer Risk of Patients with Prevalent Type 2 Diabetes Mellitus in Hungary (Part 2)
Abonyi‐Tóth, Z., Rokszin, G., Sütő, G., Fábián, I., Kiss, Z., Jermendy, G., Kempler, P., Lengyel, C., Wittmann, I., & Molnár, G. A. (2024) · Cancers · doi:10.3390/cancers16132414 · Cited by 5
“In recent decades, cardiovascular and renal risk have become the Cancers 2024 , 16 , 2414 2 of 18 focus of treatment of T2DM [2].”
BackgroundCarew, A. S., Warren, R. A., Bancks, M. P., Espeland, M. A., Bahnson, J. L., Lewis, C. E., Levy, A. P., Sapp, J. L., Urquhart, R., Wang, J. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02448-z · Cited by 7
“Several diabetes organizations have released recommendations to healthcare providers emphasizing the importance of personalizing glycemic goals and treatment plans for patients with T2DM, focusing on person-centered care and shared decision-making [9–11].”
BackgroundHenson, J. J., Hernández, G., Drebert, Z. J., Slater, T., Hall, A. P., Khunti, K., Sargeant, J. A., Zaccardi, F., Davies, M. J., & Yates, T. E. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111887 · Cited by 9
Self-citationXiong, B., He, L.-M., Zhang, A., & Ling, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-81954-2 · Cited by 7
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“Thiazolidinediones (TZDs) are peroxisome proliferator– activated receptor gamma (PPARγ) agonists indicated for the T2DM management [241, 260].”
Pabla, P., Mallinson, J. E., Nixon, A., Keeton, M., Cooper, S., Marshall, M. J., Jacques, M. F., Brown, S. A., Johansen, O. E., Cuenoud, B. M., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.12.022 · Cited by 6
“Because current guidelines from health organizations [2] recommend changes in dietary and physical activity patterns as important factors for management of hyperglycaemia in T2D, there is a need for innovative and feasible nutritional approaches that can reduce PPG.”
Battista, S., Recenti, F., Kiadaliri, A., Lohmander, S. L., Jönsson, T., Abbott, A. D., Vinblad, J., Rolfson, O., Englund, M., & Dell’Isola, A. (2025) · RMD Open · doi:10.1136/rmdopen-2024-005133 · Cited by 5
Cui, W., Li, Y., Li, N., Chan, K. K., & Piao, C. (2025) · Endocrinology · doi:10.1210/endocr/bqaf040 · Cited by 5
Fadini, G. P., Ciardullo, S., Perseghin, G., Giordano, C. S. D. S., Maddaloni, E., Buzzetti, R., Ghiani, M., & Avogaro, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01729-4 · Cited by 5
“…of life as a driver of basal insulin initiation was observed, striking when viewed in the context of the American Diabetes Association/European Association for the Study of Diabetes (ADA/ EASD) consensus document, which emphasizes a patient-centred approach to holistic diabetes management [26].”
Insomnia and Cardiometabolic Health: Bridging the Gap Between Sleep Deficit and Disease Prevention
Kim, J. W., Jain, A., & Khullar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.008 · Cited by 10
Colletta, A., Cooper, K. M., Placentino, G., Devuni, D., & Colletta, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1531295 · Cited by 6
Cardoso, P., Young, K., Hopkins, R., Mateen, B. A., Pearson, E. R., Hattersley, A. T., McKinley, T. J., Shields, B. M., & Dennis, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16470 · Cited by 5
“9,12 Although multiple other factors can lead to a perceived lack of medication efficacy or access to medication, 4,13 short-term side-effects are likely the main reason for early discontinuation.”
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
“Currently, the 2022 ADA and the European Association for the Study of Diabetes guidelines for management of hyperglycemia in T2D have highlighted the roles of GLP-1 RA in reducing HbA1c, MACE, and in chronic overweight management[139].”
Narcolepsy and cardiovascular health: A big picture perspective
Grandner, M. A., Morse, A. M., Avidan, A. Y., Kushida, C. A., Krahn, L. E., Weaver, C., & Gudeman, J. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106640 · Cited by 5
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
Malik, R. A., Anderson, J., Russo, G. T., Amani, M. E. A., Adaş, M., Alvarez, A., Lauand, F., Li, X., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16591 · Cited by 5
Aldafas, R., Crabtree, T. S. J., Vinogradova, Y., Gordon, J. P., & IDRIS, I. R. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166489 · Cited by 7
“0% as the standard glycemic treatment goal [22], whereas the International Diabetes Federation recommends a level of less than 6.”
BackgroundTsai, Y.-Y., Kuo, T., Lin, M., Shen, F., & Lin, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14102 · Cited by 7
“Updated type 2 diabetes management guidelines therefore emphasize the importance of glycemic control and avoiding therapeutic inertia 6 .”
BackgroundInfluentialPérez, A., Redondo‐Antón, J., Romera, I., Lizán, L., Santos, M. R., Díaz‐Cerezo, S., & Orozco‐Beltrán, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01503-4 · Cited by 9
“Weight management should be a priority in the treatment of T2D and needs to be addressed early, preferably using weight-beneficial agents, with the aim of achieving weight loss goals ranging from 5 to 15% for many people [7, 19].”
BackgroundMethodInfluentialErbakan, A. N., Bahadır, M. A., Kaya, F. N., Güleç, B., Keskinler, M. V., Faydalıel, Ö., Mesçi, B., & Oğuz, A. (2023) · Medicine · doi:10.1097/md.0000000000036680 · Cited by 5
“[2] According to the UKPDS study, a 1% lower HbA1c resulted in remarkable reductions in microvascular complications, myocardial infarctions, and diabetes-related deaths by approximately 37%, 14%, and 21%, respectively.”
MethodMitigating Pathogenesis for Target Discovery and Disease Subtyping
Strobl, E. V., Lasko, T. A., & Gamazon, E. R. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108122 · Cited by 6
Liu, Q., Ma, L., Chen, F., Zhang, S., Huang, Z., Zheng, X., Chen, Z., Ye, J., Hou, N., Yi, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116325 · Cited by 6
Cardiovascular Risk Factors in China
Hu, S. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.02.008 · Cited by 12
Murayama, A. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13533 · Cited by 6
Zareini, B., Sørensen, K. K., Pedersen‐Bjergaard, U., Fosbøl, E. L., Køber, L., & Torp-Pedersen, C. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13560 · Cited by 4
Ishii, H., Maeda, Y., Sato, M., Cai, Z., & Imori, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01584-9 · Cited by 4
Giorda, C. B., Rossi, A., Baccetti, F., Zilich, R., Romeo, F., Nreu, B., Cianni, G. D., Guaita, G., Morviducci, L., Muselli, M., et al. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.006 · Cited by 6
Current Obstacles (With Solutions) in Type 2 Diabetes Management, Alongside Future Directions
Belančić, A., Majanović, S. K., & Rahelić, D. (2023) · Diabetology · doi:10.3390/diabetology4030031 · Cited by 5
Algoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023
Soidán, F. J. G. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.2.art2 · Cited by 5
Bucci, T., Nabrdalik, K., Shantsila, A., Romiti, G. F., Teo, W. S., Park, H. W., Shimizu, W., Tse, H., Proietti, M., Chao, T., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051274 · Cited by 7
“No data are available about the most recent antidiabetic treatments with sodium–glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist because the study enrolment period was before the publication of the most recent guidelines for DM management [46].”
BackgroundTakahashi, A., Nomoto, H., Onishi, K., Manda, S., Miya, A., Kameda, H., Nakamura, A., & Atsumi, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15639 · Cited by 5
Čatić, T., & Jusufovic, R. (2019) · Materia Socio Medica · doi:10.5455/msm.2019.31.141-145 · Cited by 5
Young, K., McInnes, E. H., Massey, R. J., Kahkohska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · medRxiv · doi:10.1101/2023.04.21.23288868 · Cited by 5
Ardesch, F. H., Geurten, R. J., Struijs, J. N., Ruwaard, D., Bilo, H. J. G., & Elissen, A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.011 · Cited by 4
Multi-target mechanisms of diabetic inhibitory peptides derived from longan seed protein hydrolysate
Kuptawach, K., Sangtanoo, P., Nutho, B., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106652 · Cited by 4
García‐Ríos, A., Romero‐Cabrera, J. L., Alcala-Diaz, J. F., Quintana‐Navarro, G. M., Martín‐Piedra, L., Larriva, A. P. A.-D., Torres-Peña, J. D., Rodríguez-Cantalejo, F., Kales, S. N., Ordovás, J. M., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20119 · Cited by 4
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recognized this in their 2024 consensus report, recommending research into sleep patterns and chronotypes—innate cycles of sleep and wakefulness—as new cardiovascular risk factors [7–9].”
Alarfaj, S. J. (2025) · Medicina · doi:10.3390/medicina61081393 · Cited by 6
“Current guidelines recommend that healthcare providers should consider not only the glucose-lowering effects of prescribed medications, but also their potential impact on body weight [7].”
Evidence-Based Synthesis for Practice: Lifestyle Interventions in Type 2 Diabetes with Obesity
Wang, H., Chen, F., Zhang, Q., Chen, J., Zhang, W., Fang, L., & Xiong, P. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s550776 · Cited by 5
Cheng, J., Li, J., Xin, Y., & Zhang, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1602796 · Cited by 5
Shirani, A., & Stüve, O. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2587277 · Cited by 7
Cardio-renal-metabolic (CRM): Call for action for European Guidelines for Primary Care Physicians
Säemann, M. D., Biesiada, A. M., Smatana, M., & Liebermann, N. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251379732 · Cited by 7
Stem cell therapy: a paradigm shift in reversing type 1 diabetes mellitus
Mouzzam, A. M., Ahmed, A., Aamir, A., Sharma, G., Sarwath, S., D'Moss, J., Namala, K., Zehra, M., Ali, M. F., Zulfiqar, M. S., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004147 · Cited by 4
“Despite advances in insulin delivery systems, achieving optimal glycemic control remains challenging, and patients are at risk of long-term complications such as retinopathy, nephropathy, and cardiovascular disease [ 15 ] .”
Rossafi, B., Abchır, O., Guerguer, F., Abass, K. S., Yamari, I., Kouali, M. E., Samadi, A., & Chtita, S. (2026) · Pharmaceuticals · doi:10.3390/ph19010098 · Cited by 8
“Furthermore, the symptoms of diabetes can differ depending on the type and individual factors, but common manifestations include frequent urination, excessive thirst, unexplained weight loss, fatigue, blurred vision, and numbness or tingling in the extremities [4,5].”
Corrao, S., Scibetta, S., Mirarchi, L., Amodeo, S., Corrao, G., & Calvo, L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113243 · Cited by 4
Hofer, G., Goode, S., Renström, F., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113263 · Cited by 4
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
Self-citationWelch, M., Forst, T. M., Jia, W., del Pino, P. O., Denning, M., Wu, W.-S., Li, J., Liu, R., EIFU, M., Chen, Y., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00800-7 · Cited by 7
Stewart, K. D., Matza, L. S., Patel, H., & Boye, K. S. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00614-7 · Cited by 6
Longo, M., Caruso, P., Scappaticcio, L., Maiorino, M. I., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15451 · Cited by 4
Kuntiyong, P., Buaphan, A., Sirirak, J., Booranamonthol, S., Khlongkhlaeo, P., Thammapichai, K., & Sanongkiet, S. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.133907 · Cited by 4
Aroda, V. R., NIELSEN, N. F., Mangla, K. K., Multani, J. K., Divino, V. M., Namvar, T., & RAJPURA, J. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003825 · Cited by 8
Self-citationLind, N., Christensen, M. B., Hansen, D. L., Willaing, I., & Nørgaard, K. (2024) · Diabetic Medicine · doi:10.1111/dme.15321 · Cited by 6
Hennies, N., Görgens, S. W., Killer, J., Otto, T., Richter, L. M., Müller‐Wieland, D., & Häckl, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15931 · Cited by 4
“3,15,16 The current understanding of CVD and obesity comorbidity profiles among patients with T2D in Germany is limited, and it is not known whether the changes in guideline recommendations are already reflected in routine care.”
Ming, A., Clemens, V., Lorek, E., Wall, J., Alhajjar, A., Galazky, I., Baum, A.-K., Li, Y., Li, M., Stober, S., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/52323 · Cited by 6
“Notably, with early diagnosis, preventive measures may be taken, such as weight control or normalization of hyperglycemia [45].”
Xu, P., Morishige, J., Jing, Z., Nagata, N., Shi, Y., Iba, T., Daikoku, T., Ono, M., Maida, Y., Fujiwara, T., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116567 · Cited by 5
Regufe, V. M. G., Lobão, M. A. R., Martins, N. A., Luís, C., HAFE, P. V., & Pinto, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216423 · Cited by 12
“However, despite the availability of various treatments, such as medication, insulin administration, dietary changes, and regular physical activity, many people with T2DM are unable to maintain adequate blood glucose control, resulting in a low efficacy rate [11,12].”
BackgroundInfluentialOsunde, R. N., Olorunfemi, O., Edwards, O. S., Oduyemi, R. O., & Sodimu, J. O. (2025) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_19_24 · Cited by 11
The impact of carbohydrate quality on gut health: Insights from the NHANES
Hu, L., Huang, X., Liu, S., Fang, L., Zhang, J., & Tang, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315795 · Cited by 4
“…are often accompanied by multiple chronic conditions, and medication and the condition itself may have a complex impact on bowel function, such as the use of diuretics and calcium channel blockers, which often interfere with normal faecal excretion, mitigating the effects of carbohydrates [47].”
Li, Y., Kar, S., Li, C., Liu, M. R., Luan, Z., Yuan, G., Zhong, X., & Mu, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01701-2 · Cited by 5
“International guidelines recommend initiating treatment with basal insulin, administered subcutaneously at least once daily, when T2D is inadequately controlled by non-insulin glucose-lowering agents [5–7].”
de Oliveira, D. D. F. M., Henriques, M. A., Nogueira, P., & da Costa, A. C. J. S. (2025) · Health & Social Care in the Community · doi:10.1155/hsc/6765353 · Cited by 4
“Te contents of the diferent intervention categories were based on evidence from the literature and international recommendations for self-care in T2DM [36–38].”
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
“Due to the lack of specific guidelines, DM management in NET patients should generally conform to the recommendations of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [130].”
The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases
Moustafa, B., & Trifan, G. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01425-7 · Cited by 7
“…(EASD) recommend adding GLP-1 receptor agonist to metformin in patients with established atherosclerotic cardiovascular disease, including ischemic stroke [ 46]. of SGLT2 reduces the reabsorption of the filtered glucose and promotes urinary excretion, without stimulating insulin release [ 53].”
Lim, S. K., Nam, G. E., & Sharma, A. M. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0278 · Cited by 6
“Guidelines from the ADA, EASD, and WHO consistently emphasize these parameters, enabling structured treatment pathways and individualized therapeutic goals [7,8].”
Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group
Irace, C., Avogaro, A., Bertuzzi, F., Buzzetti, R., Candido, R., Prato, S. D., Bartolo, P. D., Fiorina, P., Giorda, C. B., & Giorgino, F. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70059 · Cited by 7
“T2D is a complex condition, often requiring multifactorial behavioural and pharmacological treatments in an attempt to achieve a glycaemic target, avoid complications, and improve quality of life (QoL) [23].”
Self-citationAgonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Philis‐Tsimikas, A., Aberle, J., BAJAJ, H. S., Lingvay, I., Mu, Y., Shaikh, S. S., Vianna, A. G. D., Watada, H., & Prato, S. D. (2025) · Drugs · doi:10.1007/s40265-025-02201-0 · Cited by 11
“Insulin therapy is typically initiated in individuals with T2D when glycemic targets are no longer achieved with non-insulin glucose-lowering medications, when such medications are contraindicated or not tolerated, or in cases of severe hyperglycemia with metabolic decompensation [3].”
Self-citationLiu, B., Huang, R., Zhang, W., Tian, J. H., Xian, Y., & Chen, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-02394-0 · Cited by 7
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
Retnakaran, R. R., Pu, J., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01781-z · Cited by 4
Urakami, T. (2023) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2023-0007 · Cited by 6
Pulleyblank, R., & Larsen, N. B. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00416-z · Cited by 7
“For treatment of T2D amongst patients without preexisting cardiovascular or renal complications who are not adequately controlled on metformin (with or without sulfonylurea), in order to reduce HbA1c levels, international [13] and Danish [14] guidelines recommend intensifying with anti-diabetic treatment options such…”
BackgroundInfluentialKaku, K., Nakayama, Y., Yabuuchi, J., Naito, Y., & Kanasaki, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2213477 · Cited by 4
“The 2022 consensus report from the American Diabetes Association and the European Association for the Study of Diabetes on the management of hyperglycemia in T2D patients suggests that SGLT2 inhibitors should be considered for first-line glucose-lowering therapy in T2D patients with established or high risk of cardiov…”
BackgroundVijayakumar, V., Mavathur, R. N., Kannan, S., Sharma, M. N. K., Raguram, N., & Kuppusamy, M. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101457 · Cited by 5
Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?
Rossing, P. R., Frimodt‐Møller, M., & Persson, F. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151430 · Cited by 5
Self-citationShabnam, S., Abner, S. C., Gillies, C., Davies, M. J., DEX, T. A., Khunti, K., Webb, D. R., Zaccardi, F., & Seidu, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15337 · Cited by 4
Self-citationRomano, I., & Serra, R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01489-z · Cited by 5
“On the basis of guidelines, metformin is commonly the first-line therapy, but, when metformin is no longer sufficient to maintain satisfactory glucose levels, other treatment classes including oral or injectable agents can be added [2, 3].”
InfluentialAlotaibi, M., Alnajjar, F., Alsayed, B. A., Alhmiedat, T. A., Marei, A. M., Bushnag, A., & Ali, L. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s435492 · Cited by 6
“20,21 For heart disease, remote monitoring systems with personalized alerts aid in early cardiac anomaly detection, reducing hospitalizations and improving patient quality of life.”
BackgroundEghtedari, M., Goodarzi-Khoigani, M., Shahshahani, M. S., Javadzade, H., & Abazari, P. (2023) · Iranian Journal of Nursing and Midwifery Research · doi:10.4103/ijnmr.ijnmr_59_22 · Cited by 8
“[2] In response, Diabetes Self‑Management Education and Support (DSMES) has emerged as a framework for improving patient outcomes.”
BackgroundMethodRosenberg, D. E., Cruz, M., Mooney, S. J., Bobb, J. F., Drewnowski, A., Moudon, A. V., Cook, A. J., Hurvitz, P. M., Lozano, P., Anau, J., et al. (2024) · Health & Place · doi:10.1016/j.healthplace.2024.103216 · Cited by 4
Huang, C., & Lee, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051387 · Cited by 4
“The joint recommendations from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) suggest metformin as the first-line drug in glycemic management and the use of GLP-1 RA and SGLT2is with proven benefits in high-risk patients [17].”
BackgroundTabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzík, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
“Current guidelines such as ADA/EASD and AACE support the concept of simplifying the treatment regimen to decrease treatment complexity and burden, particularly for insulin therapy, which may in turn improve adherence and glycaemic control [5, 7, 21, 92].”
InfluentialAlRuthia, Y. S., Aburisheh, K. H., Ata, S. I., Salleeh, R. B., Alqudhibi, S. B., Alqudhibi, R. B., Alkraidis, Z., Alkhalaf, H. H., Almogirah, A. A., Mujammami, M. H., et al. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102057 · Cited by 4
Kamath, S. D., Kumar, U., & Shrivastava, V. (2024) · Cureus · doi:10.7759/cureus.58341 · Cited by 4
Joshi, A. S., Singh, H., & Kalra, S. (2024) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.039.01.15 · Cited by 4
Yoon, J., Lee, D., Song, H. J., Hong, D., Park, J. S., Hong, C.-H., An, K. M., Lee, J. W., Park, J.-T., Yoon, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117044 · Cited by 4
Pai, L., Hung, C., Chen, L.-L., Lin, R.-L., & Lockwood, C. S. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.08.003 · Cited by 9
LEWIS, G. A., Irving, G. J., Wilding, J. P. H., & Hardy, K. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15430 · Cited by 4
Common mistakes concerning diabetes management in daily clinical practice
Makrilakis, K., & Papachristoforou, E. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.004 · Cited by 6
Radić, J., Vučković, M., Đogaš, H., Grubić, M., Belančić, A., Tandara, L., Šegvić, L. Š., Novak, I., & Radić, M. (2024) · Medicina · doi:10.3390/medicina60101643 · Cited by 4
Tsai, M.-H., Chien, W.-C., Lin, H., Chung, C., Chen, L., Huang, K., & Lin, H. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108898 · Cited by 5
García‐Villarino, M., Martínez‐Camblor, P., García, A. V., Villa-Fernández, E., Pérez‐Fernández, S., Lambert, C., Pujante, P., Fernández-Suárez, E., Chiara, M., Torre, E. L. M., et al. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.01.007 · Cited by 8
Popoviciu, M. S., Salmen, T., Reurean‐Pintilei, D., Voiculescu, V. M., & Stoian, A. P. (2025) · Medicina · doi:10.3390/medicina61030548 · Cited by 5
“Typically, in patients with longer DM duration, insulin resistance (IR) [17–22] is more prevalent, negatively influencing responses to therapy and accelerating the development of chronic complications [23–29].”
Gan, L., Chen, P., Zhang, Z., He, X., Wu, X., Chen, Z., Wei, Q., & Wu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-94360-z · Cited by 4
An overview of the FreeStyle Libre monitoring system for individuals with type 1 and type 2 diabetes
Molfetta, S. D., Cutruzzolà, A., Gnasso, A., & Irace, C. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2489494 · Cited by 4
“Accordingly, CGM has become the gold standard for the management of T1D, and guidelines strongly suggest its use also in insulin-treated T2D individuals who can use the device safely, regardless of the number of daily insulin injections [13,17–19].”
Malinovská, J., Lustigová, M., Michalec, J., Krollová, P., Frühaufová, A., Bučková, L., Romanová, A., Beňová, K., Povolná, E., Guru, E. S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98876-2 · Cited by 5
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.